乳腺癌相关淋巴水肿患者的危险因素及种族和民族差异
这项前瞻性队列研究在三级癌症中心纳入304例接受腋窝淋巴结清扫的乳腺癌女性,24个月乳腺癌相关淋巴水肿(BCRL)累积发生率为23.8%(95% CI 17.9%-29.8%),且随种族和民族显著变化;多变量分析显示黑人种族、西班牙裔、接受新辅助化疗、年龄较大和随访间隔较长与BCRL风险升高独立相关,ERBB2阳性亚型与风险降低相关。
要点
- 24个月BCRL发生率为23.8%,黑人37.2%、西班牙裔27.7%、亚裔22.5%、白人19.8%(P=0.004)。
- 接受新辅助化疗者24个月BCRL发生率29.3%,高于初始手术者11.1%(P=0.01)。
- 多变量分析中黑人种族OR 3.88、西班牙裔OR 3.01、新辅助化疗OR 2.10、年龄每增1岁OR 1.04、随访每增6个月OR 1.57。
核心结论
- 黑人种族、西班牙裔、接受新辅助化疗、年龄较大和随访间隔较长与BCRL风险独立相关,ERBB2阳性亚型与BCRL风险降低相关。
- 作者认为需要开展研究评估BCRL种族和民族差异背后的生物学机制,以及在不常达到淋巴结病理完全缓解的肿瘤亚型中以新辅助化疗替代腋窝淋巴结清扫的替代方案。
研究设计与样本
- 前瞻性BCRL筛查研究,在三级癌症中心纳入18岁及以上接受乳腺手术和单侧腋窝淋巴结清扫(初始或前哨淋巴结活检后)的乳腺癌女性。
- 2016年11月至2020年3月共纳入304例患者,276例有至少1次纵向测量并纳入分析。
- 中位(IQR)年龄48(40-57)岁,中位(IQR)体重指数26.4(22.5-31.2)。
- 276例中29例(11%)自认亚裔、55例(20%)黑人、16例(6%)西班牙裔、166例(60%)白人、10例(3%)种族和民族未知;70%接受新辅助化疗,93%接受淋巴结放疗。
主要发现
- 24个月BCRL发生率为23.8%(95% CI 17.9%-29.8%),随种族和民族显著变化:黑人37.2%、西班牙裔27.7%、亚裔22.5%、白人19.8%(P=0.004)。
- 接受新辅助化疗者24个月BCRL发生率29.3%,高于初始手术者11.1%(P=0.01)。
- 多变量分析中,与白人相比黑人种族OR 3.88(95% CI 2.14-7.08)、西班牙裔OR 3.01(95% CI 1.10-7.62),P均<0.001。
- 多变量分析中,与初始手术相比接受新辅助化疗OR 2.10(95% CI 1.16-3.95,P=0.01),年龄每增加1岁OR 1.04(95% CI 1.02-1.07,P=0.001),随访间隔每增加6个月OR 1.57(95% CI 1.30-1.90,P<0.001)。
- 与激素受体阳性/ERBB2阴性相比,ERBB2阳性亚型与BCRL风险降低相关:OR 0.50(95% CI 0.23-0.99,P=0.04)。
关键数值与推荐
- BCRL定义为臂体积(perometer)较基线相对体积变化≥10%。
- 采用竞争风险分析评估BCRL累积发生率,采用单变量和多变量分析评估危险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Risk factors for breast cancer-related lymphedema (BCRL) after axillary lymph node dissection (ALND) are poorly understood. OBJECTIVE: To evaluate rates of and risk factors associated with BCRL in a prospective cohort of women treated with ALND. DESIGN, SETTING, AND PARTICIPANTS: This prospective BCRL screening study performed at a tertiary cancer center enrolled women with breast cancer 18 years and older undergoing breast surgery and unilateral ALND in the primary setting or after sentinel lymph node biopsy. EXPOSURES: Risk of BCRL during the first 2 years after ALND and radiotherapy. MAIN OUTCOMES AND MEASURES: Patients were prospectively evaluated with arm volume (perometer) measurements, and BCRL was defined as a relative volume change of 10% or greater from baseline. Cumulative incidence of BCRL was assessed using competing risk analysis. Risk factors for BCRL were assessed on univariate and multivariable analyses. RESULTS: From November 2016 to March 2020, 304 patients were enrolled; 276 had at least 1 longitudinal measurement. Median (IQR) age was 48 (40-57) years; median (IQR) body mass index, calculated as weight in kilograms divided by height in meters squared, was 26.4 (22.5-31.2). Of the 276 patients included in the analysis, 29 (11%) self-identified as Asian, 55 (20%) as Black, 16 (6%) as Hispanic, 166 (60%) as White, and 10 (3%) as unknown race and ethnicity; 70% received neoadjuvant chemotherapy (NAC); 93% received nodal irradiation. The 24-month BCRL rate was 23.8% (95% CI, 17.9%-29.8%), with significant variation by race and ethnicity (24-month rate: 37.2% [Black], 27.7% [Hispanic], 22.5% [Asian], and 19.8% [White]; P = .004). The BCRL rates were also higher among patients receiving NAC vs up-front surgery (24-month rate: 29.3% vs 11.1%; P = .01). On multivariable analysis, Black race and Hispanic ethnicity (compared with White race) (odds ratio [OR], 3.88; 95% CI, 2.14-7.08 and OR, 3.01; 95% CI, 1.10-7.62, respectively; P < .001 for each), receipt of NAC (compared with up-front surgery) (OR, 2.10; 95% CI, 1.16-3.95; P = .01), older age (OR, 1.04; 95% CI, 1.02-1.07 per 1-year increase; P = .001), and a longer follow-up interval (OR, 1.57; 95% CI, 1.30-1.90 per 6-month increase; P < .001) were independently associated with an increased risk of BCRL, while ERBB2-positive subtype was associated with a decreased risk of BCRL (compared with hormone receptor positive/ERBB2 negative): OR, 0.50; 95% CI, 0.23-0.99; P = .04). CONCLUSION AND RELEVANCE: In this cohort study, Black race, Hispanic ethnicity, NAC receipt, older age, and longer follow-up were independently associated with risk of BCRL. Studies are warranted to evaluate the biologic mechanisms behind racial and ethnic disparities in BCRL development and alternatives to NAC to avoid ALND in tumor subtypes unlikely to achieve nodal pathologic complete response.
引用
- Montagna G, Zhang J, Sevilimedu V, et al. Risk Factors and Racial and Ethnic Disparities in Patients With Breast Cancer-Related Lymphedema. JAMA Oncol. 2022. PMID: 35679026. doi:10.1001/jamaoncol.2022.1628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。